Jens Juul Holst (University of Copenhagen) Q&A: A conversation with GLP-1 co-discoverer Jens Juul Holst on the future of incretin-based drugs Medicines based on glucagon-like peptide-1 (GLP-1) have revolutionized the treatment of diabetes and obesity
However, not everyone responds equally
These membrane-bound long-chain PUFAs are susceptible to oxidation, particularly under stressful conditions, subsequently triggering cell ferroptosis [191]
Unlike small molecules that may lack selectivity, or large proteins that face delivery challenges, peptides often provide an optimal balance of specificity, potency, and manufacturability
Develop cooking skills
Likewise, first- and second-phase insulin secretion and insulin sensitivity were increased, while postprandial plasma glucose concentrations and plasma glucagon concentrations were lowered